We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-6.99%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.74B
AUM Growth
-$513M
Cap. Flow
+$325M
Cap. Flow %
6.86%
Top 10 Hldgs %
55.75%
Holding
72
New
10
Increased
16
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$149M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$82M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$48.7M
4
APGE icon
Apogee Therapeutics
APGE
+$47.2M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$31.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$103M
2
ISRG icon
Intuitive Surgical
ISRG
+$58.1M
3
ILMN icon
Illumina
ILMN
+$31.8M
4
AXNX
Axonics, Inc. Common Stock
AXNX
+$24.9M
5
MRVI icon
Maravai LifeSciences
MRVI
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$362M 7.65%
17,687,772
– –
IMCR icon
2
Immunocore
IMCR
$1.78B
$316M 6.68%
6,096,387
+66,754
+1% +$3.95M
AXSM icon
3
Axsome Therapeutics
AXSM
$12.4B
$314M 6.62%
4,489,596
+205,319
+5% +$15.3M
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$36.3B
$298M 6.29%
1,683,362
– –
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$295M 6.22%
6,768,514
+2,295,529
+51% +$82M
ARGX icon
6
argenx
ARGX
$57.4B
$249M 5.26%
507,195
+25,000
+5% +$12.2M
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.25B
$241M 5.09%
11,576,537
+1,793,288
+18% +$48.7M
BRKR icon
8
Bruker
BRKR
$9.2B
$211M 4.45%
3,381,703
+422,100
+14% +$28.4M
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.65B
$193M 4.07%
5,405,089
– –
PEN icon
10
Penumbra
PEN
$12.5B
$163M 3.44%
673,371
– –
PTCT icon
11
PTC Therapeutics
PTCT
$6.37B
$162M 3.42%
7,235,196
– –
TMO icon
12
Thermo Fisher Scientific
TMO
$211B
$147M 3.1%
290,334
– –
MASI
13
DELISTED
Masimo
MASI
$132M 2.78%
1,501,493
– –
ESTA icon
14
Establishment Labs
ESTA
$2.72B
$122M 2.58%
2,494,138
– –
NTRA icon
15
Natera
NTRA
$37.5B
$117M 2.48%
2,651,783
+40,000
+2% +$2.04M
VCEL icon
16
Vericel Corp
VCEL
$2.3B
$110M 2.33%
3,291,873
– –
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$106M 2.24%
+5,149,482
New +$149M
CLDX icon
18
Celldex Therapeutics
CLDX
$2.77B
$95.3M 2.01%
3,463,201
– –
PTGX icon
19
Protagonist Therapeutics
PTGX
$8.75B
$90.3M 1.91%
5,415,514
– –
CYTK icon
20
Cytokinetics
CYTK
$11B
$75.8M 1.6%
2,574,198
– –
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$73.5M 1.55%
7,136,415
+325,774
+5% +$4.36M
TXG icon
22
10x Genomics
TXG
$5.87B
$62.7M 1.32%
1,519,956
+57,000
+4% +$2.97M
TSHA icon
23
Taysha Gene Therapies
TSHA
$1.59B
$53.4M 1.13%
+16,893,185
New +$31.6M
TARS icon
24
Tarsus Pharmaceuticals
TARS
$2.56B
$51.2M 1.08%
2,880,701
+332,576
+13% +$5.89M
OBIO icon
25
Orchestra BioMed
OBIO
$224M
$49M 1.03%
5,620,640
– –
1
2 3

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q3 2023 Portfolio in Review

As of Q3 2023, RTW Investments held 72 positions worth $4.74B, down 9.8% from $5.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

RTW Investments deployed $325M of net new capital in Q3 2023, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Sage Therapeutics: 5,149,482 shares worth $106M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Illumina, an estimated $31.8M trimmed.

  • RTW Investments's largest Q3 2023 buy was Sage Therapeutics: 5,149,482 shares worth $106M.
  • RTW Investments added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $82M increase.
  • RTW Investments's biggest Q3 2023 reduction was Illumina, cutting an estimated $31.8M.
  • RTW Investments fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023, selling an estimated $103M.
  • RTW Investments's ten largest holdings make up 56% of its $4.74B portfolio in Q3 2023.
  • RTW Investments opened 10 new positions and closed 5 in Q3 2023.
  • RTW Investments's portfolio value fell 9.8% quarter-over-quarter to $4.74B.

Based on RTW Investments's 13F filing for Q3 2023, filed 14 Nov 2023.